Wavelength Pharmaceuticals Inc.

Wavelength Pharmaceuticals Inc. is a specialized company focused on developing and providing pharmaceutical solutions aimed at enhancing healthcare efficiency and effectiveness through innovative technologies and strategic partnerships. Founded in 1987 in Petah Tikva, Israel, Wavelength Pharmaceuticals Inc. operates in the pharmaceutical sector.

The company was formed following the acquisition of Perrigo API Limited by SK Capital, which was completed in November 2017. Wavelength Pharmaceuticals has not publicly disclosed any changes in its business strategy or operations since its inception. The acquisition aimed to support the company's growth and profitability by investing in people, culture, processes, and technology. Wavelength Pharmaceuticals specializes in developing innovative pharmaceutical solutions designed to improve operational efficiency in healthcare settings.

Their product offerings include advanced formulations and delivery systems that integrate cutting-edge technology to address specific healthcare challenges. The company's diverse client base spans small and medium enterprises, as well as larger healthcare providers, primarily in North America and Europe. Since its founding, Wavelength Pharmaceuticals has focused on continuous innovation and enhancement of its product offerings to meet the evolving needs of the healthcare market. Wavelength Pharmaceuticals generates revenue through a variety of channels, including direct sales of their pharmaceutical products and strategic collaborations with healthcare providers.

The company has established a subscription-based revenue model for certain services, allowing clients to access their innovative solutions while ensuring predictable revenue streams. The firm has positioned itself within the market by offering high-quality products that cater to the unique demands of healthcare clients, fostering long-term partnerships. Wavelength Pharmaceuticals plans to launch new pharmaceutical products in the coming years, with a focus on integrating advanced technologies into their formulations. The company aims to penetrate emerging markets in Asia and Latin America by 2025, leveraging its recent acquisition and subsequent investment in operational capabilities.

The recent Buyout round, completed in August 2017 for USD 110 mn, will be utilized to enhance product development, expand their workforce, and improve manufacturing processes, ensuring the company is well-positioned for its next phase of growth.